Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

Core Viewpoint - Enzo Biochem, Inc. intends to voluntarily delist its common stock from the NYSE and transition to the OTCQX Best Market due to non-compliance with NYSE listing standards [1][3]. Delisting Announcement - The company provided notice of the voluntary delisting to the NYSE on March 28, 2025, with the delisting expected to be effective around April 17, 2025, and trading on OTCQX to begin on or about April 18, 2025 [2][4]. - The decision follows a notice from the NYSE regarding non-compliance with market capitalization, stockholder's equity, and average closing stock price requirements [3]. Compliance and Reporting - Enzo Biochem has applied for quotation on the OTCQX and expects to be quoted the next trading day after NYSE trading ceases, pending OTCQX approval [4]. - The company will continue to adhere to the periodic reporting requirements of the Securities Exchange Act of 1934 after the delisting [5]. Company Overview - Enzo Biochem has been a life sciences company for over 45 years, primarily operating through its Life Sciences division, focusing on labeling and detection technologies [6]. - The company offers a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals, and proteins, which are essential in translational research and drug development [6].